Full-Time

Product Manager/Senior Product Manager

HCP Marketing, Alzheimer’s Disease Agitation

Confirmed live in the last 24 hours

Axsome Therapeutics Inc

Axsome Therapeutics Inc

201-500 employees

Develops therapies for CNS disorders

Biotechnology
Healthcare

Compensation Overview

$120k - $160kAnnually

+ Annual Bonus + Equity

Mid, Senior

New York, NY, USA

On-site requirement of at least three days per week; unable to consider candidates looking for fully remote roles.

Category
Product Marketing
Product
Required Skills
Market Research
Marketing
Data Analysis

You match the following Axsome Therapeutics Inc's candidate preferences

Employers are more likely to interview you if you match these preferences:

Degree
Experience
Requirements
  • BA or BS, advanced degree preferred
  • 4-6 years of experience in the pharmaceutical industry including a minimum of 2 years in marketing
  • Demonstrated ability to manage budget and resources
  • Demonstrated ability to achieve results in a highly matrixed organization
  • Ability to achieve cross-functional project specific goals under tight timelines
  • Strong project and process management skills, including competency in agency management and budget management
  • Excellent verbal and written communication skills
  • Launch experience strongly preferred
  • Ability to work on-site Monday, Tuesday, and Thursday. We are unable to consider candidates who are looking for fully remote role
Responsibilities
  • Lead the development and facilitation of key initiatives aligned with personal promotion and field sales initiatives
  • Develop key tactics to support personal promotion strategy
  • Collaborate with agency and cross-functional partners
  • Support brand initiatives including but not limited to peer-to-peer education, conference planning, brand planning, and non-personal promotion
  • Identify appropriate measurements & ROI and develop comprehensive reporting to evaluate effectiveness personal promotion initiatives
  • Lead reviews of promotional materials with Regulatory/Legal/Medical
  • Collaborate effectively with sales & marketing, market access, patient support, market research, medical affairs, commercial operations, data & analytics, finance, and other cross-functional partners
  • Identify strategic market opportunities and make recommendations to enhance brand penetration
  • Handle timelines and budgets in accordance with brand plan
Desired Qualifications
  • Demonstrated proactive, creative and entrepreneurial approach
  • CNS disease experience
  • Comfortable with uncertainty and high expectations
  • Experience developing, implementing, and working on successful multichannel campaigns
  • Strong digital marketing aptitude
  • Strong interpersonal and presentation skills
Axsome Therapeutics Inc

Axsome Therapeutics Inc

View

Axsome Therapeutics develops therapies for central nervous system (CNS) disorders, focusing on conditions like major depressive disorder, treatment-resistant depression, and Alzheimer's agitation. Their main product, AXS-05, is an oral medication that works by blocking NMDA receptors in the brain, which helps regulate mood. This drug has shown positive results in clinical trials and has received FDA Breakthrough Therapy Designation, allowing for faster development and review. Unlike many competitors, Axsome emphasizes addressing unmet medical needs in CNS disorders and aims to improve patient outcomes through rigorous research and clinical trials. The company's goal is to bring effective treatments to market, enhancing the quality of life for patients suffering from these conditions.

Company Size

201-500

Company Stage

IPO

Total Funding

$430.7M

Headquarters

New York City, New York

Founded

2012

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA's fast-tracking of CNS treatments could expedite Axsome's drug approvals.
  • Increased investment in CNS R&D drives innovation, benefiting Axsome's pipeline.
  • Growing personalized medicine trend offers Axsome opportunities for tailored therapies.

What critics are saying

  • Increased competition from companies like Compass Pathways in the CNS market.
  • Potential delays in AXS-07 launch amid growing market anticipation.
  • Departure of key personnel like Lori Englebert may impact strategic direction.

What makes Axsome Therapeutics Inc unique

  • Axsome focuses on CNS disorders with limited current treatment options.
  • AXS-05, an NMDA receptor antagonist, targets major depressive disorder and treatment-resistant depression.
  • Axsome's balanced portfolio includes both clinical and research stage products.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Performance Bonus

Company Equity

Company News

Investing.com
Dec 19th, 2024
Amgen stock touches 52-week low at $257.77 amid market shifts

The firm sees potential in Sarepta's Elevidys for Duchenne muscular dystrophy, Legend's ability to double its manufacturing capacity, and Axsome's anticipated launch of AXS-07 for migraines.

MarketBeat
Dec 13th, 2024
Captrust Financial Advisors Invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Captrust Financial Advisors invests $514,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 4th, 2024
Erste Asset Management GmbH Invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Erste Asset Management GmbH invests $986,000 in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Dec 2nd, 2024
PDT Partners LLC Makes New $1.05 Million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

PDT Partners LLC makes new $1.05 million Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Nov 29th, 2024
FORA Capital LLC Makes New $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

FORA Capital LLC makes new $994,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

MarketBeat
Nov 28th, 2024
Intech Investment Management LLC Makes New $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Intech Investment Management LLC makes new $983,000 Investment in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Investing.com
Sep 27th, 2024
Wall Street SWOT: Axsome stock fortified by robust IP and CNS market potential

Axsome Therapeutics, Inc. (NASDAQ:AXSM) has emerged as a prominent player in the biopharmaceutical industry, focusing on developing novel therapies for central nervous system (CNS) disorders.

MarketBeat
Aug 1st, 2024
Castleark Management LLC Invests $2.57 Million in Axsome Therapeutics, Inc. (NASDAQ:AXSM)

Castleark Management LLC invests $2.57 million in Axsome Therapeutics, Inc. (NASDAQ:AXSM).

Yahoo Finance
Jul 30th, 2024
Axsome Therapeutics, Inc.'s (NASDAQ:AXSM) Shift From Loss To Profit

Axsome Therapeutics, Inc., a biopharmaceutical company, engages in the development of novel therapies for central nervous system (CNS) disorders in the United States.

Stock Titan
Jun 26th, 2024
Compass Pathways appoints Lori Englebert as Chief Commercial Officer

Lori brings multifaceted experience in global pharmaceuticals and joins from Axsome Therapeutics, where she spent nearly five years as a member of the executive team serving as head of commercial and business development and most recently as head of product strategy.